康莱特注射液联合化疗治疗多发性骨髓瘤的临床疗效观察

目的观察康莱特注射液联合化疗对多发性骨髓瘤患者的疗效以及对免疫功能的影响。方法69例多发性骨髓瘤患者分为试验组和对照组。实验组（34例）予VAD方案化疗结合康莱特注射液静脉滴注；对照组（35例）予VAD方案化疗，每4周重复一次该化疗方案，2次化疗疗程结束后评价疗效。69例患者均在开始化疗前及2次化疗疗程结束后采集外周静脉血，用流式细胞仪检测T细胞亚群CD3＋、CD4＋。结果实验组中CR26例，总缓解率8513％；对照组中总缓解率88．6％，两组比较缓解率差异无统计学意义（P〉0．05），不良反应差异有统计学意义（P〈0．05），实验组患者治疗前与治疗后外周血中CD3＋、CD4＋细胞数量无统计学意义（P〉0．05）：而对照组患者治疗后与本组治疗前及实验组治疗后比较外周血中CD3＋、CD4＋细胞数量有统计学意义（P〈0．05）。结论康莱特结合VAD方案化疗能降低化疗副反应，同时能增强多发性骨髓瘤患者的免疫功能，且不良反应低。

Clinical observation on patients with multiple myeloma treated by Kanglaite injection combined with concurrent chemo-therapy

Objective To observe the effectivity and immunity of Kanglaite injection combined with concurrent chemo-therapy on multiple myeloma（MM）. Methods A total of 69 patients of stage MM patients were divided into two groups： 34 cases in treatment group（ VAD ehemo-therapy combined with Kanglaite injection）, 35 cases in eontol group （VAD chemo-therapy）. The program was repeated once every four weeks. Eight weeks later, the effects were assessed by testing the qualities of CD3＋,CD4＋ in peripheral blood. Results In treatment group, total effective rate （CR＋PR） was 85.3%; In contol group,the total efficiency was 88.6%,treatment group had the same efficiency as that of control group （P 〉 0.05）. Toxicity was lower in treatment group than that in control group. The qualities of CD3＋,CD4＋ were higher in treatment group than that in control group before therapy. Conclusion Kanglaite injection combined with concurrent chemo-therapy can significantly improve the immunity of multiple myeloma（MM）, and decrease the toxicity.